HC Wainwright reissued their buy rating on shares of aTyr Pharma (NASDAQ:LIFE – Free Report) in a research note issued to investors on Wednesday, Benzinga reports. The brokerage currently has a $35.00 price target on the biotechnology company’s stock. Separately, StockNews.com lowered aTyr Pharma from a hold rating to a sell rating in a research […]